Daiwa Securities Group
NTLA icon

Daiwa Securities Group’s Intellia Therapeutics NTLA Stock Holding History

Daiwa Securities Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,536
Closed -$68K – 1355
2025
Q4 		$68K Buy
7,536
+410
+6% +$5.64K ﹤0.01% 1072
2025
Q3 		$123K Sell
7,126
-645
-8% -$7.94K ﹤0.01% 1026
2025
Q2 		$73K Buy
7,771
+2,788
+56% +$22.9K ﹤0.01% 1018
2025
Q1 		$35K Sell
4,983
-168
-3% -$1.7K ﹤0.01% 1047
2024
Q4 		$60K Buy
5,151
+2,299
+81% +$35.9K ﹤0.01% 1050
2024
Q3 		$59K Sell
2,852
-31
-1% -$715 ﹤0.01% 1053
2024
Q2 		$65K Sell
2,883
-5
-0.2% -$119 ﹤0.01% 1069
2024
Q1 		$79K Sell
2,888
-168
-5% -$4.67K ﹤0.01% 1068
2023
Q4 		$93K Buy
3,056
+793
+35% +$22.8K ﹤0.01% 1024
2023
Q3 		$72K Hold
2,263
– – ﹤0.01% 1038
2023
Q2 		$92K Buy
2,263
+64
+3% +$2.6K ﹤0.01% 1021
2023
Q1 		$82K Buy
2,199
+370
+20% +$14.5K ﹤0.01% 1005
2022
Q4 		$64K Buy
1,829
+102
+6% +$4.85K ﹤0.01% 1010
2022
Q3 		$97K Sell
1,727
-447
-21% -$27.7K ﹤0.01% 1006
2022
Q2 		$113K Buy
2,174
+1,957
+902% +$99.4K ﹤0.01% 1011
2022
Q1 		$16K Hold
217
– – ﹤0.01% 1120
2021
Q4 		$26K Sell
217
-35
-14% -$4.38K ﹤0.01% 1109
2021
Q3 		$34K Buy
252
+118
+88% +$17.9K ﹤0.01% 1081
2021
Q2 		$22K Hold
134
– – ﹤0.01% 1016
2021
Q1 		$11K Buy
134
+23
+21% +$1.54K ﹤0.01% 1044
2020
Q4 		$6K Sell
111
-177
-61% -$6.43K ﹤0.01% 1049
2020
Q3 		$6K Hold
288
– – ﹤0.01% 1077
2020
Q2 		$4K Hold
288
– – ﹤0.01% 1123
2020
Q1 		$4K Hold
288
– – ﹤0.01% 1118
2019
Q4 		$4K Hold
288
– – ﹤0.01% 1127
2019
Q3 		$4K Hold
288
– – ﹤0.01% 1091
2019
Q2 		$5K Buy
288
+54
+23% +$849 ﹤0.01% 1100
2019
Q1 		$4K Hold
234
– – ﹤0.01% 1093
2018
Q4 		$3K Hold
234
– – ﹤0.01% 1092
2018
Q3 		$7K Hold
234
– – ﹤0.01% 1066
2018
Q2 		$6K Hold
234
– – ﹤0.01% 1085
2018
Q1 		$5K Buy
+234
New +$5.75K ﹤0.01% 1076

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Daiwa Securities Group's NTLA Position: Q1 2026 in Review

Daiwa Securities Group sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 7,536 shares — an estimated $68K sold.

Daiwa Securities Group first reported a position in NTLA in Q1 2018 and held it in 32 quarters. The position peaked at $123K in Q3 2025. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Daiwa Securities Group reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 7,536 Intellia Therapeutics shares in Q1 2026, an estimated $68K.
  • Daiwa Securities Group first reported a position in Intellia Therapeutics in Q1 2018 and held it in 32 quarters.
  • Daiwa Securities Group's Intellia Therapeutics position peaked at $123K in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.